Treasury’s biotech proposal spares licensing; Canada and Türkiye set trade talks · Politics · October 24, 2026 · Orbis Signal
Politics
Treasury’s biotech proposal spares licensing; Canada and Türkiye set trade talks
Biotech · COINS Act · Canada–Türkiye
5 min read
Executive summary
The biotechnology provisions of Treasury’s October 22 outbound-investment proposal would prohibit covered investment in pharmaceutical compounds, research tools and production facilities involving countries of concern such as China. Equity stakes, convertible debt, greenfield expansions and joint ventures would be restricted, while standard contractual in-licensing and fee-for-service research would remain excluded. Separately, Canada and Türkiye established a strategic partnership with a three-year action plan and scheduled their first formal free-trade negotiating round for November 30–December 4 in Ankara. The developments suggest two different routes for cross-border business: contractual biotechnology collaboration could remain open despite investment restrictions, while Canadian–Turkish project cooperation could advance separately from tariff negotiations.
Key judgments
1
Treasury’s proposed exemption for standard in-licensing and fee-for-service research suggests biotechnology collaboration could shift from equity financing toward contracts rather than stop altogether. Cross-border drug licensing accounted for approximately $136 billion in deal volume in 2025.
InferenceModerate confidence
2
The proposed restrictions on biomanufacturing facilities, bioinformatics tools and automated discovery software indicate that compliance screening would need to cover research infrastructure as well as drug assets.
InferenceHigh confidence
3
Canada and Türkiye established a strategic partnership on October 22, 2026, with a three-year action plan covering trade, defence, energy and people-to-people ties. Their first formal free-trade negotiating round is scheduled for November 30–December 4 in Ankara.
ConfirmedHigh confidence
4
EDC and Türk Eximbank’s signed framework for joint financing and co-insurance suggests the partnership’s first commercial openings could be third-country projects rather than new bilateral tariff preferences.
InferenceModerate confidence
Why this matters
For pharmaceutical business development, continued access to licensed discoveries would not establish that overseas developers and manufacturing capacity remain adequately financed. If the proposal is adopted substantially as drafted, pipeline access and the ability to fund the underlying research could diverge. That distinction matters for delivery milestones, development obligations and the durability of a collaboration—not just its legal structure.
Strategic implications
Bundled biotechnology deals would require commercial and technical diligence within the same approval process. An excluded research contract would not necessarily make an associated equity investment, convertible instrument or facility expansion permissible.
Canada’s diversification could extend through Canadian engineering and Turkish construction partnerships in Africa, Central Asia and the Middle East. This suggests a broader commercial route than simply increasing bilateral exports.
The defence-industry agreement creates a separate channel for Canadian and Turkish manufacturers to identify partners. Its commercial significance will depend on firm-level arrangements rather than progress in the FTA negotiations alone.
Uncertainty register
Unresolved variables that could shift the assessment materially.
The final biotechnology definitions, exemption boundaries and implementation timetable remain unsettled. December 7, 2026, is the public-comment deadline, not an established compliance commencement date.
The EDC–Türk Eximbank memorandum does not establish transaction-level funding commitments, financing terms or disbursements.
The FTA negotiations have not begun. The eventual tariff and services coverage, negotiating timetable and agreement prospects remain unknown.
Decision relevance
Operating impact
Pending biotechnology deals could require restructuring and revised development-funding assumptions. Technical diligence would need to establish whether research tools or production capacity bring an otherwise contractual collaboration within the investment restrictions.
Rules
Internal transaction approval would need to test both financing instruments and covered technical activities. If adopted, non-compliance could trigger maximum IEEPA civil penalties and Treasury-mandated divestment; December 7 is the comment deadline, not the compliance start date.
Footprint
U.S.-linked biotechnology collaborations in covered jurisdictions face different treatment for ownership and contractual access. The Canadian–Turkish project framework identifies opportunities in Africa, Central Asia and the Middle East; it does not create bilateral tariff preferences.
Decisions this bears on
Choose the structure of a pending China-linked biotechnology collaboration—licensing, contract research, equity or a joint venture—with development funding and access rights at stake.
Set approval conditions for a covered biomanufacturing expansion or automated-discovery investment, given the draft's inclusion of facilities and research software.
Decide whether to submit technical comments before December 7 on biotechnology definitions that could capture the company's tools, platforms or transaction structures.
Consensus gap
Coverage centered on a licensing carve-out and bilateral trade targets underweights transaction-level evidence. The useful tests are whether biotechnology deals are actually restructured or cancelled, and whether Canadian–Turkish cooperation produces named projects with executable terms. Those outcomes would distinguish commercial adaptation from policy announcements.
Signal events
Confirmed
Biotechnology draft distinguishes investment from contractual research
Treasury’s October 22 COINS Act proposal would restrict covered equity stakes, convertible debt, greenfield expansions and joint ventures while excluding standard contractual in-licensing and fee-for-service research. The proposed enforcement framework includes maximum civil penalties under IEEPA and Treasury-mandated divestment of non-compliant transactions. Public comments close December 7, 2026.
3 sources
Confirmed
Proposed biotechnology scope reaches compounds, facilities and software
The pharmaceutical-compound definition includes small molecules, polymers, vaccines, blood products, allergenics, cell and gene therapies, and delivery systems. The draft also reaches biomanufacturing equipment and facilities, bioinformatics tools, biological design and sequencing technologies, brain-computer interfaces, and automated discovery software.
2 sources
Confirmed
Carney and Erdoğan launch partnership with staged trade ambitions
Canadian Prime Minister Mark Carney and Turkish President Recep Tayyip Erdoğan established the partnership in Ankara on October 22. Erdoğan set objectives to increase annual bilateral trade from roughly $3 billion to an interim $5 billion and ultimately $10 billion. The outreach forms part of Canada’s effort to diversify commercial relationships and reduce exposure to U.S. protectionism.
Watchlist
Indicators and developments to monitor in the coming days.
Treasury revisions that narrow or expand the treatment of pharmaceutical compounds, bioinformatics, automated discovery software or biomanufacturing facilities.
Industry submissions before December 7 and subsequent Treasury guidance on licensing linked to equity or joint ventures; an implementation date would establish a separate compliance milestone.
Completed biotechnology restructurings from equity or joint ventures into licensing or contract research would support the substitution judgment; cancellations citing unavailable development financing would weaken it.
Specific tariff or services offers and a negotiating timetable emerging from the November 30–December 4 FTA round in Ankara.
The first EDC–Türk Eximbank project with named participants, committed financing and specified co-insurance terms.
Select Canadian–Turkish partners and financing assumptions for a third-country project bid, distinguishing the export-credit framework from committed funding.
3 sources
Confirmed
Export-credit and defence agreements add project-level channels
Export Development Canada and Türk Eximbank signed a memorandum providing a framework for joint project financing and co-insurance in Africa, Central Asia and the Middle East. Canadian Foreign Minister Anita Anand and Türkiye’s Defence Industry Agency President Haluk Görgün also signed an Agreement on Defence Industry Partnership to connect manufacturers in the two countries.